Schering Corporation

Merck Sharp + Dohme Corp.

Intervet Inc.

Schering-Plough Animal Health Corporation

Terrill K McClanahan

Daniel M Gorman

Erin E Murphy

Robert A Kastelein

Jeanine D Mattson

Karin Franz-Bacon

Joseph H Phillips

Lewis L Lanier

Jason R Chan

Gosse Jan Adema

Linde Meyaard

Gerard Zurawski

Sandra M Zurawski

Christi L Parham

Martin Oft

Theodore R Sana

Mark David Ayers

Michael V Nebozhyn

Andrey Loboda

Jeffery Grein

Hirokazu Kurata

Naoko Arai

Jared K Lunceford

Chetan Savkoor

Kathleen M Smith

J Fernando Bazan

Albert Zlotnik

Rene De Waal Malefyt

Kurt C Gish

Wolfgang Seghezzi

Maribel Beaumont

Emma M Lees

Heather Hirsch

Jennifer R Louten

Frances Shanahan

Laurel M Bolin

M Jorge Guimaraes

A gene expression platform, which is a combination of a set of genes that are correlated with response to a PD-1 antagonist in multiple tumor types and a normalization gene set, is disclosed. A method and system of using the gene expression platform to derive gene signature biomarkers of anti-tumor response to a PD-1 antagonist and to test patient samples for predictive gene signature biomarkers are also disclosed.

System and methods for deriving gene signature biomarkers of response to PD-1 antagonists

The present disclosure describes baseline and on treatment blood-based gene signature biomarkers that are predictive of tumor sensitivity to therapy with a PD-1 antagonist. The on-treatment biomarkers comprise a PD-L1 gene signature or an interferon gamma gene signature and the baseline gene signature biomarker comprises genes associated with the oxidative phosphorylation pathway. The disclosure also provides methods and kits for testing tumor samples for these biomarkers, as well as methods for treating subjects with a PD-1 antagonist based on the test results.

Blood-based biomarkers of tumor sensitivity to PD-1 antagonists

The present invention relates to biomarker responsive to treatment with an anti-Thymic Stromal Lymphopoietin (TSLP) antibody.

Biomarkers for TSLP treatment

Nucleic acids encoding mammalian, e.g., primate or rodent, genes, purified proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are provided.

Nucleic acids encoding TNF&#x3b3;

Nucleic acids encoding a new family of small cysteine rich soluble proteins, from a mammal, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided.

Methods of making antibodies specific for cysteine-rich soluble protein C23

Provided are methods for diagnosing the propensity of a subject to develop skin inflammation, in particular, psoriasis. Also provided are methods of treatment with antagonists of IL-17, IL-19, and/or IL-23.

Method of treating skin inflammation

Nucleic acid encoding TNFx protein

Provided are methods of treatment for tumors. In particular, methods are provided for modulating activity of a cytokine molecule and its receptor.

Methods of inhibiting tumor growth using blocking antibodies to IL-23R

The present invention provides isolated nucleic acid molecules that encode a substantial part of canine RANKL polypeptide, including the extracellular domains of that polypeptide, the polypeptide and fragments thereof. Vectors and host cells encoding and expressing canine RANKL polypeptide are provided, as well as antibodies that bind to RANKL and that inhibit RANKL activity. Also provided are methods of treating an animal to inhibit or treat the loss of bone minerals.

Canine RANKL and methods for preparing and using the same

Nucleic acids encoding various monocyte cell proteins from a primate, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using reagents and related diagnostic kits are also provided.

Antibodies that bind DNAX leukocyte associated immunoglobulin-like receptor

Provided are methods for diagnosing the propensity of a subject to develop skin inflammation, in particular, psoriasis. Also provided are methods of treatment with antagonists of IL-17 and/or IL-23.

Method of treatment of skin inflammation

Binding compounds specific for cysteine-rich soluble protein C23

C23 Polypeptides

Growing community of inventors

Sunnyvale, CA, United States of America

Terrill K McClanahan